Novartis Announces Fourth US Radioligand Therapy Facility in Winter Park, Florida

Novartis plans to build a new 35,000-square-foot radioligand therapy (RLT) manufacturing facility in Winter Park, Florida, marking its fourth US site, expected online by 2029.13

The project is part of Novartis's $23 billion US manufacturing investment announced in April 2025.123

RLT is a precision cancer treatment delivering targeted radiation to tumors while sparing healthy tissue; Novartis maintains >99% on-time dose administration.13

Additional expansions include facilities in Indiana, New Jersey, a recently completed site in California, and a planned fifth US location.23

CEO Vas Narasimhan stated the facility ensures speed and reliability for RLT medicines.13

One report mentions a $70M investment for the site at 3825 Forsyth Road.9

Sources:

1. https://pharma.economictimes.indiatimes.com/news/pharma-industry/novartis-to-set-up-new-radioligand-therapy-facility-in-florida-under-23-bn-us-mfg-push/126435904

2. https://www.morningstar.com/news/dow-jones/202601095057/novartis-to-build-radioligand-therapy-facility-in-florida

3. https://www.novartis.com/news/media-releases/novartis-add-radioligand-therapy-manufacturing-facility-winter-park-florida-fourth-us-serve-patients-and-advance-23-billion-investment

9. https://www.bizjournals.com/orlando/news/2026/01/09/florida-orlando-winter-park-novartis-new-facility.html